Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (2019)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1056/NEJMoa1911303
- Subjects: INSUFICIÊNCIA CARDÍACA; DIABETES MELLITUS NÃO INSULINO-DEPENDENTE; PROTEÍNAS DE TRANSPORTE; RESULTADO DE TRATAMENTO; ESTUDOS PROSPECTIVOS
- Agências de fomento:
- Vifor Pharma
- Boehringer IngelheimBoehringer Ingelheim
- Eidos Therapeutics
- Sanofi Pasteur
- Mesoblast
- Lonestar Heart
- Ionis Pharmaceuticals
- Celladon
- Bellerophon Therapeutics
- Cytokinetics
- BayerBayer AG
- Theracos
- NovartisNovartis
- MyoKardia
- GlaxoSmithKlineGlaxoSmithKline
- Gilead SciencesGilead Sciences
- Bristol-Myers SquibbBristol-Myers Squibb
- AmgenAmgen
- Alnylam Pharmaceuticals
- AstraZenecaAstraZeneca
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: New england journal of medicine
- ISSN: 0028-4793
- Volume/Número/Paginação/Ano: v. 381, n. 21, p. 1995-2008, 2019
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
MCMURRAY, J. J. V et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New england journal of medicine, v. 381, n. 21, p. 1995-2008, 2019Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1911303. Acesso em: 19 set. 2024. -
APA
Mcmurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Kober, L., Kosiborod, M. N., Martinez, F. A., et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New england journal of medicine, 381( 21), 1995-2008. doi:10.1056/NEJMoa1911303 -
NLM
Mcmurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Nicolau JC. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [Internet]. New england journal of medicine. 2019 ; 381( 21): 1995-2008.[citado 2024 set. 19 ] Available from: https://doi.org/10.1056/NEJMoa1911303 -
Vancouver
Mcmurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Nicolau JC. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [Internet]. New england journal of medicine. 2019 ; 381( 21): 1995-2008.[citado 2024 set. 19 ] Available from: https://doi.org/10.1056/NEJMoa1911303 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1056/NEJMoa1911303 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas